This activity was produced prior to the accelerated FDA approval of mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma following treatment with at least 2 prior lines of systemic therapy.

Optimizing Clinical Outcomes with JAK Inhibition in the Management of Inflammatory Bowel Disease: Burden, Unmet Needs, And Novel Therapeutic Options

PROGRAM CHAIR

Miguel Regueiro, MD, FACP, FACG, AGAF
Chair, Digestive Disease and Surgery Institute
Chair, Department of Gastroenterology, Hepatology and Nutrition
Professor, Department of Medicine
Cleveland Clinic
Cleveland, OH

PROGRAM OVERVIEW

This CME program provides a comprehensive and up-to-date perspective on the evolving management of patients with inflammatory bowel disease (IBD). We will be discussing unmet needs in the current identification and management of IBD; identifying tools to assist with differential diagnosis, clinical assessment, and selection of effective therapies for IBD; and exploring the underlying pathophysiology of IBD and the role of JAK inhibition in modifying therapeutic outcomes.

TARGET AUDIENCE

This STRIVE Initiative along with its micro-learning opportunities and enduring online 2D Ultra 4K HD program is intended for gastroenterologists, primary care physicians, nurse practitioners, nurses, pharmacists, and other members of the multidisciplinary team to ensure optimal patient outcomes in the management of IBD.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Summarize the role of JAK/STAT signaling in the underlying pathophysiology of IBD and the role of JAK inhibition in modifying therapeutic outcomes.
  • Recognize major unmet needs in IBD and options for further improvement in clinical outcomes through application of novel therapy.
  • Update knowledge and competence in the differential diagnosis, clinical assessment, and selection of effective therapies for IBD management.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with IBD.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Miguel Regueiro, MD Discloses that he receives research support from AbbVie, Janssen, and Takeda; unrestricted educational grants from AbbVie, Janssen, UCB, Pfizer, Takeda, Salix, and Shire; honoraria for advisory boards and consultant for AbbVie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, and Allergan

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Christopher Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
  • Rashado Coote, Program Coordinator for Med Learning Group, has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy‐policy/.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: September 20, 2022

EXPIRATION DATE: September 20, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top